
doi: 10.1136/bmj.a2186
pmid: 18948345
“You’d be mad not to protect your daughter against genital warts if you can afford to.” So advised Peter Greenhouse, a sexual health consultant in Bristol, when I asked him which human papillomavirus vaccine I should choose for my daughter. The NHS vaccination programme may have opted for the bivalent vaccine (Cervarix) to concentrate resources on preventing cervical cancer, but every doctor I’ve spoken to has chosen the quadrivalent vaccine (Gardasil) for their own daughters (and the odd son, though of course this is off licence). Genital warts are common (100 000 new cases in England each year), and the condition is on the rise, particularly among young people: in women 60% of cases occur in the 16-24 years age group. They don’t kill you, but they can kill your sex life, and in some people they can be recurrent and extensive. The health minister Dawn Primarolo claims that warts are “preventable,” but meticulous condom use cuts transmission of the human papillomavirus by only 50%. A far safer option is to vaccinate. The NHS Choices website (www.nhs.uk) promotes Cervarix but doesn’t return a single hit for Gardasil. Having chosen one vaccine for …
Adult, Parents, Adolescent, Health Policy, Prescription Fees, Uterine Cervical Neoplasms, Choice Behavior, State Medicine, United Kingdom, Government Programs, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Condylomata Acuminata, Humans, Female, Papillomavirus Vaccines
Adult, Parents, Adolescent, Health Policy, Prescription Fees, Uterine Cervical Neoplasms, Choice Behavior, State Medicine, United Kingdom, Government Programs, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Condylomata Acuminata, Humans, Female, Papillomavirus Vaccines
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 2 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
